IMB Dx (KOSDAQ:A461030) - Stock Price, News & Analysis

A461030 Stock Overview

Provides liquid biopsy platform in South Korea. More details

A461030 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Volatile share price over the past 3 months compared to the KR market

IMB Dx, Inc. Competitors

Kangstem Biotech

KOSDAQ:A217730

₩142.7b

Anterogen.Co.Ltd

KOSDAQ:A065660

₩147.9b

NIBEC

KOSDAQ:A138610

₩153.9b

Helixmith

KOSDAQ:A084990

₩139.8b

Price History & Performance

Summary of all time highs, changes and price drops for IMB Dx
Historical stock prices
Current Share Price	₩10,920.00
52 Week High	₩40,550.00
52 Week Low	₩8,430.00
Beta	0
11 Month Change	-23.15%
3 Month Change	-50.59%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-69.67%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	A461030	KR Biotechs	KR Market
7D	-5.6%	-3.5%	2.5%
1Y	n/a	24.9%	-1.1%

Return vs Industry: Insufficient data to determine how A461030 performed against the KR Biotechs industry.

Return vs Market: Insufficient data to determine how A461030 performed against the KR Market.

Price Volatility

Is A461030's price volatile compared to industry and market?
A461030 volatility
A461030 Average Weekly Movement	9.9%
Biotechs Industry Average Movement	8.0%
Market Average Movement	5.7%
10% most volatile stocks in KR Market	11.6%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A461030's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A461030's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
2018	n/a	Tae-You Kim	www.imbdx.com

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection.

IMB Dx, Inc. Fundamentals Summary

How do IMB Dx's earnings and revenue compare to its market cap?
A461030 fundamental statistics
Market cap	₩152.23b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A461030 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A461030 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A461030 perform over the long term?

See historical performance and comparison